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Identification and characterization 
of the BRI2 interactome in the brain
Filipa Martins1, Ana M. Marafona1, Cátia D. Pereira1, Thorsten Müller2,3,4, Christina Loosse2, 
Katharina Kolbe2,3,4, Odete A. B. da Cruz e Silva1 & Sandra Rebelo1
BRI family proteins are ubiquitous type II transmembrane proteins but BRI2 is highly expressed in 
some neuronal tissues. Possible BRI2 functions include neuronal maturation and differentiation. 
Protein complexes appear to be important in mediating its functions. Previously described BRI2 
interactors include the Alzheimer’s amyloid precursor protein and protein phosphatase 1, but clearly 
the identification of novel interactors provides an important tool to understand the role and function of 
BRI2. To this end three rat brain regions (cerebellum, hippocampus, and cerebral cortex) were processed 
by BRI2 immunoprecipitation; co-precipitating proteins were identified by Nano-HPLC-MS/MS. The 
pool of the brain regions resulted in 511 BRI2 interacting proteins (BRI2 brain interactome) of which 
120 were brain specific and 49 involved in neuronal differentiation. Brain region-specific analyses were 
also carried out for cerebellum, hippocampus, and cerebral cortex. Several novel BRI2 interactors were 
identified among them DLG4/PSD-95, which is singularly important as it places BRI2 in the postsynaptic 
compartment. This interaction was validated as well as the interaction with GAP-43 and synaptophysin. 
In essence, the resulting BRI2 brain interactome, associates this protein with neurite outgrowth and 
neuronal differentiation, as well as synaptic signalling and plasticity. It follows that further studies 
should address BRI2 particularly given its relevance to neuropathological conditions.
BRI2 (also known as ITM2B, integral membrane protein 2B) is a ubiquitously expressed type II transmembrane 
protein that belongs to a family comprising two additional members, BRI1 and BRI3. BRI2 mRNA was found 
highly expressed in the brain, placenta, pancreas, and kidney, whereas lower expression levels were observed in 
heart, lung, liver and skeletal muscle. Remarkably, in the brain, BRI2 is predominantly detected in the cerebellum, 
spinal cord, subthalamic nucleus, substantia nigra, and hippocampus. However, lower expression levels were 
detected in the cerebral cortex, amygdala and thalamus1. Moreover, using in situ hybridization it was demon-
strated that within the brain, BRI2 mRNA is distributed in different cellular populations, namely in neurons, 
astrocytes, and microglial cells as well as in smooth muscle and cerebral endothelial cells2. Subcellularly, BRI2 is 
mainly localized in the endoplasmic reticulum (ER), Golgi apparatus, plasma membrane and cytoplasmic ves-
icles3. BRI2 undergoes regulated intramembrane proteolysis (RIP) in the cis- or medial-Golgi resulting in the 
formation of several secreted peptides, including the C-terminal 23-residue peptide, the BRICHOS domain, the 
NTF and BRI2 C-terminal domain, and an intracellular domain (BRI2ICD), as consequence of the activity of 
several proteases3.
The distribution of BRI2 within proximal dendrites and axons, as well as cell bodies, and its presence in 
some neuropathological structures like dystrophic neurites, suggests that BRI2 could be anterogradely trans-
ported to the nerve terminals, where it may have a role4. In fact, BRI2 overexpression in human neuronal cells 
induces neurites’ elongation, indicating that BRI2 could be involved in neurite outgrowth3,5. Moreover, BRI2 
expression increases during neuronal maturation and differentiation suggesting an important role for BRI2 both 
during neuronal development but also in the adult brain6. In addition, some BRI2 binding proteins have been 
identified; as is the case with the Alzheimer’s amyloid precursor protein (APP). BRI2:APP interaction occurs 
at the cell surface and in endocytic compartments, and this complex could potentially regulate APP process-
ing and inhibit Abeta production7,8. Interestingly, BRI2 accumulates in the hippocampus in the early stages of 
Alzheimer’s disease (AD) preventing the BRI2:APP complex formation and therefore resulting in increased APP 
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processing and consequently more Abeta1-40 and Abeta1-42 is produced9. Additionally, we recently reported that 
BRI2 interacts with protein phosphatase 1 (PP1) via a well conserved RVxF motif (3KVTF6) located at the BRI2 
N-terminal domain. Further, we established that BRI2 is dephosphorylated by this protein phosphatase; given 
that when the BRI2:PP1 interaction is abolished, BRI2 phosphorylation levels increase dramatically. The morpho-
logical consequence of inhibiting PP1 binding was a phenotype consistent with neurite outgrowth and neuronal 
differentiation5,6.
In addition to AD, the clinical relevance of this protein lies in two different autosomal dominant mutations 
in the ITM2B gene, which are associated with two rare early-onset forms of dementia, the Familial British and 
Danish dementias (FBD and FDD, respectively). These diseases share several clinical symptoms, such as progres-
sive cognitive impairment cerebellar ataxia and spasticity10. Neuropathological hallmarks of FBD consist in the 
presence of pre-amyloid and amyloid parenchymal lesions in the brain (primarily localized to the hippocampus 
and cerebellum), extensive cerebral amyloid angiopathy (CAA) and intraneuronal formation of neurofibrillary 
tangles (NFT) within the limbic regions11,12. Neuropathological lesions in FDD patients are closely similar to 
those found in FBD, however in FDD co-deposition of Abeta and Danish amyloid is observed, but parenchymal 
compact plaques are absent13,14.
To date, the precise physiological BRI2 function is not fully elucidated. Even so several lines of evidence 
strengthen the association of BRI2 with neuronal functions, in particular, the identification and functional 
characterization of BRI2 interactors, namely APP and PP1. Therefore, the identification of novel BRI2 inter-
actors that may play important roles in regulating its trafficking, processing and signalling effect is an essential 
point. Additionally, specific cellular signalling pathways and processes which are crucial to the understanding of 
the physiological and pathological role of BRI2, in particular in the brain, may be forthcoming. The work here 
described proposes novel BRI2 interactors in rat brain, which represent a valuable tool to study the brain func-
tion in mammals. BRI2 interactors in three different brain regions were investigated; the cerebellum, hippocam-
pus, and cerebral cortex, followed by in silico analysis, such as Gene Ontology (GO), biological pathways, and 
protein-protein interaction (PPI) network analysis. This permitted identifying potentially novel BRI2 functional 
relationships via analysing its interacting proteins in the brain.
Results
Identification of BRI2 brain interactome. Given that BRI2 has been recently associated with important 
neuronal functions, the identification of BRI2 brain interactors is of paramount importance. Therefore, our main 
goal was the identification of novel putative BRI2 interacting proteins in rat brain. Given the expression pattern of 
BRI2 in the brain, three different regions were chosen, namely cerebral cortex, hippocampus and cerebellum, and 
the workflow carried out is summarized and presented in Supplementary Figure S1. Briefly, the above-mentioned 
brain regions were dissected out and subjected to co-immunoprecipitation (co-IP) using a BRI2 specific antibody 
against the N-terminal region of the protein. For the co-IP experiments, two negative controls were used for each 
specific brain region. For one of the control Dynabeads Protein G in the absence of the BRI2 antibody was added 
to the tissue lysates, while in the second control Dynabeads Protein G was conjugated with anti-mouse IgGs. The 
co-IPed proteins were analyzed by HPLC-MS/MS. The identified proteins were subjected to data processing and 
filtering; some proteins were only identified in the BRI2 co-IP samples and never in the controls, while others 
appeared both in the controls IPs and BRI2 co-IPs. These latter proteins were considered as BRI2 putative inter-
actors if the peptide spectrum matches (PSM) ratio between co-IP samples and controls ≥ 2.0. Overall, upon 
data processing 511 putative BRI2 interacting proteins were identified in the rat brain (Supplementary Table S1). 
Of note, 342 proteins were identified in the cerebral cortex, 257 in the hippocampus and 262 in the cerebellum 
(Supplementary Table S1). In Supplementary Table S1, the Uniprot accession numbers are listed as well as the 
gene and protein name, and the rat brain region in which the peptides were detected. The first analysis of the 
BRI2 brain interactome (pool of the three brain regions studied) using bioinformatic approaches indicates that 
the majority of proteins identified in this study belong to the protein classes of cytoskeletal proteins (16%; half 
of which belong to the actin family), hydrolases (12%), enzyme modulators (11%; mainly G-proteins) and trans-
porters (11%; half of which belong to cation transporters family). Other represented protein classes included 
membrane traffic proteins (7%), oxidoreductases (7%), calcium-binding proteins (5%), ion channels (5%; being 
2% anion channels), dehydrogenases (5%), chaperones (3%), structural proteins (3%), ATP synthases (2%), trans-
membrane receptor regulatory/adaptor proteins (2%) and transcription factors (1%) (Fig. 1A and Supplementary 
Table S2).
In parallel, a curated list of 45 proteins that were previously identified as putative BRI2 interacting proteins 
was retrieved, as described in methods section (Supplementary Table S3). Overall, most of these proteins were 
identified by yeast-two hybrid and high-throughput screens and were not further validated by additional assays. 
Of note, in the study here described, 2 of the 45 previously reported BRI2 interacting proteins were also iden-
tified: the dihydropyridine-sensitive L-type, calcium channel alpha-2/delta subunit (Cacna2d1) and the serine/
threonine-protein phosphatase PP1-alpha catalytic subunit (Ppp1ca).
Highly enriched and specific brain BRI2 interacting proteins. Given that the main goal of this work is 
to unravel putative associations of BRI2 to specific cellular functions as well as pathways where BRI2 participates 
in the brain related processes, a tissue-specific/enriched network approach was employed. For this purpose, the 
enriched and specific brain proteins from the candidate BRI2 pooled interactome (cerebral cortex + hippocam-
pus + cerebellum) using three different databases were retrieved, as explained in the materials and methods sec-
tion. From the 511 putative BRI2 interacting proteins identified by Nano-HPLC-MS/MS, a total of 120 proteins 
are highly enriched/specifically (ES) expressed in the brain (BRI2 ES interactome) (Table 1).
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Almost half of these interactors are cytoskeletal proteins (around 18%; mainly actin and microtubules) or 
transporters (around 18%; half of which belong to cation transporters family), followed by membrane traffic 
proteins (14%; half of which are regulatory), structural proteins (6%: half of which are myelin proteins), trans-
membrane receptor regulatory/adaptor proteins (3%) and nucleic acid binding proteins (2%) (Fig. 1B and 
Supplementary Table S4).
In order to elucidate if the proteins identified in BRI2 ES interactome could be assigned to specific functions, 
and ultimately to provide more information regarding the physiological role of BRI2, particularly in the brain, 
a further classification was performed into functional categories according to Gene Ontology (GO) annotation 
using the PANTHER online resource. Regarding the analysis of the over-represented biological process GO 
terms (Fig. 2A and Supplementary Table S5), the results revealed that the BRI2 ES interactome included proteins 
involved in several functional roles, from which the synaptic vesicle cycle (60.3%), neuron development (32.2%), 
brain development (26.4%), regulation of synaptic plasticity (24.0%), ion transport (22.3%), and cytoskeleton 
organization (16.5%) stand out (Fig. 2A). Cellular component annotation analysis revealed several statistically 
enriched categories (Supplementary Table S6). Of note, a high percentage of proteins in the BRI2 ES interactome 
that localized to the synapse (57.0%), dendrite (30.6%), postsynaptic density (25.6%), synaptic vesicle (24.0%), 
axon terminus (17.4%) and presynaptic membrane (10.7%) were found (Fig. 2B).
BRI2 role in neuronal differentiation. Previous results strongly suggested a role for BRI2 in neuronal 
differentiation4–6, however to date the exact mechanisms or pathways involving BRI2 have not been revealed. 
Hence from the BRI2 brain ES interactors, the proteins annotated with GO terms related to neuronal differenti-
ation were retrieved. This resulted in a list of 49 proteins corresponding to the BRI2 ES neuronal differentiation 
interactome (Supplementary Table S7). To evaluate the interconnection of these BRI2 candidate interactors, a PPI 
network augmentation was performed, using the Cytoscape software15, which enhanced the experimental data 
with additional known and experimentally validated PPI from public databases (see materials and methods sec-
tion). In addition, the proteins annotated with GO terms related to neuronal differentiation from the previously 
identified list of BRI2 interactors (Supplementary Table S3), were manually added to this PPI network. The PPI 
network augmentation provides interesting and valuable information, permitting a systems approach to analyze 
the complexes formed from the co-immunoprecipitating proteins rather than a single interaction.
The network construction and analysis were achieved using the NetworkAnalyzer plugin of the Cytoscape15. 
In the resulting BRI2 (gene ITM2B) PPI network (Fig. 3), the grey nodes correspond to PPI added by the 
Figure 1. Panther Protein class of the novel BRI2 interactome using the PANTHER online resource. The 
percentage of the BRI2 interacting proteins in each category was calculated and plotted. (A) Panther Protein 
class of all the identified BRI2 interacting proteins (BRI2 brain interactome). (B) Panther Protein class of the 
identified brain-enriched or specific BRI2 interacting proteins (BRI2 brain ES interactome).
www.nature.com/scientificreports/
4SCIENtIFIC RepoRts |  (2018) 8:3548  | DOI:10.1038/s41598-018-21453-3
Uniprot accession Gene name Protein name Brain regions
P13233 Cnp 2′,3′-cyclic-nucleotide 3′-phosphodiesterase CC, HP, CB
P23565 Ina Alpha-internexin CC, HP, CB
O08838 Amph Amphiphysin CC, HP, CB
P0C6S7 Anks1b Ankyrin repeat and sterile alpha motif domain-containing protein 1B CC
Q8CGU4 Agap2 Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 2 CC
Q6PST4 Atl1 Atlastin-1 CC
Q05764 Add2 Beta-adducin HP
P85969 Napb Beta-soluble NSF attachment protein HP
Q05175 Basp1 Brain acid soluble protein 1 HP
P55068 Bcan Brevican core protein HP, CB
P11275 Camk2a Calcium/calmodulin-dependent protein kinase type II subunit alpha CC, HP
P08413 Camk2b Calcium/calmodulin-dependent protein kinase type II subunit beta CC, HP, CB
Q62717 Cadps Calcium-dependent secretion activator 1 HP
Q63092 Camkv CaM kinase-like vesicle-associated protein HP
Q1WIM1 Cadm4 Cell adhesion molecule 4 CB
Q5FVI4 Cend1 Cell cycle exit and neuronal differentiation protein 1 CC, HP
Q05140 Snap91 Clathrin coat assembly protein AP180 CC, HP
P63041 Cplx1 Complexin-1 HP
Q9Z1T4 Cnksr2 Connector enhancer of kinase suppressor of ras 2 CC
Q63198 Cntn1 Contactin-1 CC, HP
P97846 Cntnap1 Contactin-associated protein 1 CC, CB
Q5BJS7 Cpne9 Copine-9 HP
Q62950 Crmp1 Dihydropyrimidinase-related protein 1 HP
Q62951 Dpysl4 Dihydropyrimidinase-related protein 4 CB
Q63622 Dlg2 Disks large homolog 2 CC
P31016 Dlg4 Disks large homolog 4 CC, HP, CB
P97836 Dlgap1 Disks large-associated protein 1 CC
P97837 Dlgap2 Disks large-associated protein 2 CC
P97838 Dlgap3 Disks large-associated protein 3 CC
P21575 Dnm1 Dynamin-1 CC, HP
Q8R491 Ehd3 EH domain-containing protein 3 HP
Q8CH84 Elavl2 ELAV-like protein 2 CC
O35179 Sh3gl2 Endophilin-A1 CC, CB
P24942 Slc1a3 Excitatory amino acid transporter 1 CC, HP, CB
P31596 Slc1a2 Excitatory amino acid transporter 2 CC, HP, CB
O35921 Slc1a6 Excitatory amino acid transporter 4 CB
O88871 Gabbr2 Gamma-aminobutyric acid type B receptor subunit 2 CC
P47819 Gfap Glial fibrillary acidic protein CC, HP, CB
P19490 Gria1 Glutamate receptor 1 CC
P19491 Gria2 Glutamate receptor 2 CC, HP, CB
P35439 Grin1 Glutamate receptor ionotropic, NMDA 1 CC
Q00960 Grin2b Glutamate receptor ionotropic, NMDA 2B CC
Q9WTT6 Gda Guanine deaminase CC
P19627 Gnaz Guanine nucleotide-binding protein G CC, HP
P59215 Gnao1 Guanine nucleotide-binding protein G CC, HP, CB
Q9Z214 Homer1 Homer protein homolog 1 CC
Q9ESM2 Hapln2 Hyaluronan and proteoglycan link protein 2 CC, CB
Q9QYU4 Crym Ketimine reductase mu-crystallin HP
Q6QLM7 Kif5a Kinesin heavy chain isoform 5 A CC, HP, CB
P56536 Kif5c Kinesin heavy chain isoform 5 C CC, CB
P37285 Klc1 Kinesin light chain 1 CC, HP, CB
Q62813 Lsamp Limbic system-associated membrane protein CC, CB
P34926 Map1a Microtubule-associated protein 1 A CC, HP
P15205 Map1b Microtubule-associated protein 1B CC, HP, CB
Continued
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Uniprot accession Gene name Protein name Brain regions
P15146 Map2 Microtubule-associated protein 2 CC
Q63560 Map6 Microtubule-associated protein 6 CC, HP, CB
Q505J6 Slc25a18 Mitochondrial glutamate carrier 2 CC
P02688 Mbp Myelin basic protein CC
P60203 Plp1 Myelin proteolipid protein CC, CB
P07722 Mag Myelin-associated glycoprotein CC, CB
Q63345 Mog Myelin-oligodendrocyte glycoprotein CC, CB
P13596 Ncam1 Neural cell adhesion molecule 1 CB
P55067 Ncan Neurocan core protein CC, HP, CB
O35095 Ncdn Neurochondrin CC
P19527 Nefl Neurofilament light polypeptide CC, HP, CB
P12839 Nefm Neurofilament medium polypeptide CC, CB
P07936 Gap43 Neuromodulin CC
Q9ESI7 Dcx Neuronal migration protein doublecortin CC
Q9WU34 Sept3 Neuronal-specific septin-3 HP
Q62718 Ntm Neurotrimin CC, CB
P11506 Atp2b2 Plasma membrane calcium-transporting ATPase 2 CC
Q64568 Atp2b3 Plasma membrane calcium-transporting ATPase 3 HP
P10499 Kcna1 Potassium voltage-gated channel subfamily A member 1 CC
Q6MG82 Prrt1 Proline-rich transmembrane protein 1 HP
O88778 Bsn Protein bassoon CC, CB
P63319 Prkcg Protein kinase C gamma type CC, HP, CB
Q9JKS6 Pclo Protein piccolo CC
P47709 Rph3a Rabphilin-3A CC, HP
P63012 Rab3a Ras-related protein Rab-3A CC, HP, CB
P62824 Rab3c Ras-related protein Rab-3C CC, HP
Q9JIR4 Rims1 Regulating synaptic membrane exocytosis protein 1 CC
Q64548 Rtn1 Reticulon-1 CC, HP, CB
Q9JKE3 Scamp5 Secretory carrier-associated membrane protein 5 CC, HP
Q9JJM9 Sept5 Septin-5 CC, HP
O08875 Dclk1 Serine/threonine-protein kinase DCLK1 CC, HP
Q9WV48 Shank1 SH3 and multiple ankyrin repeat domains protein 1 CC, CB
P0DJJ3 Sgip1 SH3-containing GRB2-like protein 3-interacting protein 1 CC, HP
P31647 Slc6a11 Sodium- and chloride-dependent GABA transporter 3 CC, CB
P48768 Slc8a2 Sodium/calcium exchanger 2 CC
P06686 Atp1a2 Sodium/potassium-transporting ATPase subunit alpha-2 CC
P06687 Atp1a3 Sodium/potassium-transporting ATPase subunit alpha-3 CC, HP
P13638 Atp1b2 Sodium/potassium-transporting ATPase subunit beta-2 CC, HP, CB
Q63633 Slc12a5 Solute carrier family 12 member 5 HP
Q9QWN8 Sptbn2 Spectrin beta chain, non-erythrocytic 2 CC, CB
Q9QXY2 Srcin1 SRC kinase signaling inhibitor 1 CC, CB
P09951 Syn1 Synapsin-1 CC, HP
Q63537 Syn2 Synapsin-2 CC
Q02563 Sv2a Synaptic vesicle glycoprotein 2 A CC, HP, CB
Q63564 Sv2b Synaptic vesicle glycoprotein 2B CC, HP
P07825 Syp Synaptophysin CC, HP
P60881 Snap25 Synaptosomal-associated protein 25 HP, CB
P21707 Syt1 Synaptotagmin-1 CC, HP, CB
P97610 Syt12 Synaptotagmin-12 CC, CB
P29101 Syt2 Synaptotagmin-2 CB
Q62747 Syt7 Synaptotagmin-7 CB
P32851 Stx1a Syntaxin-1A CC
P61265 Stx1b Syntaxin-1B CC, HP, CB
P61765 Stxbp1 Syntaxin-binding protein 1 CC, HP
Q05546 Tnr Tenascin-R CC, HP, CB
P70566 Tmod2 Tropomodulin-2 CC, CB
P85108 Tubb2a Tubulin beta-2A chain CC, HP, CB
Continued
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Cytoscape analysis, the colored nodes to the proteins identified in this study (blue for proteins identified in cer-
ebral cortex, orange for proteins identified in hippocampus, and green for proteins identified in cerebellum) 
annotated with GO terms related to neuronal differentiation, and the node size corresponds to its degree (k; 
the number of edges linked to it). The total number of proteins mapped in the neuronal differentiation-specific 
PPI network was 144 (nodes), and the total number of connections between them was 286 (edges) (Fig. 3). The 
average number of neighbors for a node in the network, which indicates the average connectivity of a node in the 
network, is 3.972. The mean clustering coefficient of the network, which characterizes how nearest neighboring 
nodes of a node are connected to each other, is 0.09, being 4.5 times larger than the clustering coefficient expected 
for a sparse random uncorrelated network (0.02)16,17.
From all the nodes, the TUBB3 (k = 23) was noteworthy since it presents the highest node degree and in this 
study, it was identified in the three different brain regions analyzed (Fig. 3). TUBB3 (Tubulin beta-3 chain), is a 
neuron-specific beta-tubulin which has been suggested to have a critical role in proper axon guidance and main-
tenance18. Additionally, the following proteins were highlighted in the network: the TUBB2B (k = 16), CAMK2A 
(k = 15), CRMP1 (k = 15), MAP1B (k = 13), CAMK2B (k = 11), NEFL (k = 11), KIF5A (k = 11), NEFM (K = 10) 
and DLG4 (k = 9) (Fig. 3).
In order to establish the signalling pathways that are most associated with BRI2, an integrated KEGG pathway 
enrichment analysis of the 144 proteins in BRI2 brain ES neuronal differentiation PPI network was performed 
using the ClueGo plugin of the Cytoscape software19. This analysis placed BRI2 into signalling networks well 
Uniprot accession Gene name Protein name Brain regions
Q3KRE8 Tubb2b Tubulin beta-2B chain CC, HP
Q4QRB4 Tubb3 Tubulin beta-3 chain CC, HP, CB
Q9QUL6 Nsf Vesicle-fusing ATPase CC, HP, CB
Q62634 Slc17a7 Vesicular glutamate transporter 1 CC, HP
Q9JI12 Slc17a6 Vesicular glutamate transporter 2 CC
O35458 Slc32a1 Vesicular inhibitory amino acid transporter CC, HP
P62762 Vsnl1 Visinin-like protein 1 CB
Q71RJ2 Cacng2 Voltage-dependent calcium channel gamma-2 subunit CB
Q6QIX3 Slc30a3 Zinc transporter 3 CC
Table 1. Novel candidate BRI2 interacting proteins highly enriched or specific for the brain tissue. Uniprot 
accession numbers, gene and protein names, are listed, as well as the rat brain tissues where the proteins were 
found. CC, cerebral cortex; HP, hippocampus; CB, cerebellum.
Figure 2. Functional enrichment analysis of the BRI2 brain ES interactome using the PANTHER online 
resource. The percentage of the BRI2 interacting proteins in each category was calculated and plotted. (A) 
Biological process analysis of the identified BRI2 interacting proteins particularly brain-enriched or specific. (B) 
Cellular component analysis of the identified BRI2 interacting proteins particularly brain-enriched or specific.
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related to neuronal differentiation, namely ErbB signalling pathway (pValue = 1.812E-08), neurotrophin signal-
ling pathway (pValue = 6.443E-05), estrogen signalling pathway (pValue = 1.163E-05), FoxO signalling pathway 
(pValue = 5.248E-03), axon guidance (pValue = 1.571E-03), adherens junction (pValue = 2.896E-02) and HIF-1 
signalling pathway (pValue = 2.675E-02) (Table 2).
BRI2 brain region specific interactome. A second analytical approach used in this study of the BRI2 
interactome, took into account the different brain regions, since this could be important and may reveal differences 
providing novel insights into specific BRI2 associated brain region-dependent processes. Therefore, the identifica-
tion and characterization of the specific candidate BRI2 interactors from the three different brain regions: cerebral 
cortex, hippocampus, and cerebellum, was carried out (Fig. 4). A comparative analysis of the 511 candidate BRI2 
interacting proteins identified in this study revealed that 108 proteins were specifically identified in the cerebral 
cortex, 62 in the hippocampus and 85 in the cerebellum (Fig. 4A). Further, 92 proteins were common to all regions, 
while 61 were shared by the cerebral cortex and cerebellum, 23 between cerebellum and hippocampus and 80 
between cerebral cortex and hippocampus (Fig. 4A and B). Furthermore, given the particular interest in studying 
BRI2 function(s) in the CNS (central nervous system), a comparative analysis of the BRI2 ES interactome was also 
carried out (Fig. 4C). The results evidenced that while the majority of proteins were shared between brain regions 
(27 shared in all three regions, 17 shared in the cerebral cortex and cerebellum, 21 shared in cerebral cortex and 
hippocampus, and 2 shared in cerebellum and hippocampus), a subset of proteins were found to co-IP with BRI2 
in specific brain regions (31 in cerebral cortex, 14 in hippocampus, and 8 in cerebellum) (Fig. 4C).
Once the BRI2 ES region specific interactomes were established (Fig. 4D), network augmentation was per-
formed to enhance the experimental data with additional known and experimentally validated protein part-
ners and obtain PPI networks (BRI2 ES region-specific networks). For the cerebral cortex specific PPI network 
(Supplementary Figure S2A), a total of 292 proteins (nodes) with 330 connections (edges) between them was 
mapped. This network presents an average number of 2.243 neighbors. Regarding the hippocampus specific 
PPI network (Supplementary Figure S2B), 160 proteins, with 165 connections between them was mapped. The 
topological analysis revealed an average number of neighbors of 2.0625. The cerebellum-specific PPI network 
(Supplementary Figure S2C) was the smallest, with only 47 nodes connected by 47 edges, and with an average of 
2.0 neighbors. To further address if the BRI2 interactome could be assigned to selective brain region-dependent 
processes, functional enrichment analysis of the BRI2 ES region-specific networks, using the PANTHER online 
resource, was performed (Table 3). Remarkably, biological process annotation evidenced that for the three BRI2 
ES region-specific networks, the highly enriched terms were similar to those previously associated with the BRI2 
ES interactome, namely neuron differentiation and synaptic vesicle cycling (Table 3 and Fig. 2A).
Validation of HPLC-MS/MS-identified BRI2 interactors by immunoblotting analysis. The iden-
tification of DLG4, also known as PSD-95, synaptophysin (SYP), and GAP-43 in the BRI2 ES interactome is of 
paramount importance since it suggests the presence of BRI2 in both the pre- and postsynaptic compartments, 
Figure 3. BRI2 brain ES sub-network for neuronal differentiation annotated proteins. Node colors represent 
the source of the protein: blue nodes correspond to proteins identified in this study in the cerebral cortex, 
orange nodes correspond to proteins identified in this study in the hippocampus, green nodes correspond to 
proteins identified in this study in the cerebellum, and grey nodes are proteins added by network augmentation. 
Node size according to the degree in the network. Edge color represents the source of interaction: light red 
edges correspond to the novel BRI2 interactions identified in our study, whereas the grey edges correspond to 
interactions added by network augmentation.
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KEGG Term ID KEGG Term
Nr. 
Genes
% Associated 
Genes pValue Associated Genes Found
KEGG:04012 ErbB signaling pathway 12 13.636364 1.81E-08
ABL1, AKT1, CAMK2A, CAMK2B, 
CDKN1A, EGFR, ERBB4, GRB2, JUN, 
MYC, NCK1, SRC
KEGG:05215 Prostate cancer 10 11.235955 4.00E-06
AKT1, BCL2, CDKN1A, EGFR, GRB2, 
HSP90AA1, HSP90AB1, IKBKG, MDM2, 
TP53
KEGG:05161 Hepatitis B 12 8.219178 6.07E-06
AKT1, BCL2, CDKN1A, FOS, GRB2, 
IKBKG, JUN, MYC, SRC, STAT1, TP53, 
YWHAQ
KEGG:05014 Amyotrophic lateral sclerosis (ALS) 8 15.686275 6.07E-06 BCL2, BID, GRIN1, GRIN2B, NEFL, NEFM, TNFRSF1B, TP53
KEGG:04915 Estrogen signaling pathway 10 10.0 1.16E-05 AKT1, EGFR, ESR2, FOS, GNAO1, GRB2, HSP90AA1, HSP90AB1, JUN, SRC
KEGG:05169 Epstein-Barr virus infection 13 6.372549 3.20E-05
AKT1, BCL2, CDKN1A, CSNK2B, IKBKG, 
JUN, MDM2, MYC, TP53, TRAF6, VIM, 
YWHAG, YWHAQ
KEGG:05205 Proteoglycans in cancer 13 6.3414636 3.32E-05
AKT1, CAMK2A, CAMK2B, CDKN1A, 
EGFR, ERBB4, GRB2, MDM2, MYC, 
PPP1CA, SMAD2, SRC, TP53
KEGG:05214 Glioma 8 12.121212 4.40E-05 AKT1, CAMK2A, CAMK2B, CDKN1A, EGFR, GRB2, MDM2, TP53
KEGG:04722 Neurotrophin signaling pathway 10 8.264462 6.44E-05 ABL1, AKT1, BCL2, CAMK2A, CAMK2B, GRB2, JUN, MAP3K3, TP53, TRAF6
KEGG:05220 Chronic myeloid leukemia 8 10.958904 9.26E-05 ABL1, AKT1, CDKN1A, GRB2, IKBKG, MDM2, MYC, TP53
KEGG:04728 Dopaminergic synapse 10 7.6923075 1.20E-04 AKT1, ARRB2, CAMK2A, CAMK2B, FOS, GNAO1, GRIN2B, KIF5A, KIF5C, PPP1CA
KEGG:05219 Bladder cancer 6 14.634147 3.29E-04 CDKN1A, EGFR, MDM2, MYC, SRC, TP53
KEGG:05210 Colorectal cancer 7 11.290322 3.32E-04 AKT1, BCL2, FOS, JUN, MYC, SMAD2, TP53
KEGG:05031 Amphetamine addiction 7 10.294118 5.92E-04 CAMK2A, CAMK2B, FOS, GRIN1, GRIN2B, JUN, PPP1CA
KEGG:04921 Oxytocin signaling pathway 10 6.289308 6.65E-04 CAMK2A, CAMK2B, CDKN1A, EGFR, FOS, GNAO1, JUN, PPP1CA, RGS2, SRC
KEGG:04360 Axon guidance 10 5.681818 1.57E-03 ABL1, CAMK2A, CAMK2B, DPYSL2, FYN, NCK1, RYK, SEMA4F, SEMA6A, SRC
KEGG:05130 Pathogenic Escherichia coli infection 6 10.909091 1.70E-03
ABL1, FYN, NCK1, TUBB2B, TUBB3, 
YWHAQ
KEGG:05224 Breast cancer 9 6.1643834 2.00E-03 AKT1, CDKN1A, EGFR, ESR2, FOS, GRB2, JUN, MYC, TP53
KEGG:05222 Small cell lung cancer 7 8.139535 2.46E-03 AKT1, BCL2, IKBKG, MYC, RXRB, TP53, TRAF6
KEGG:04721 Synaptic vesicle cycle 6 9.523809 3.40E-03 RAB3A, RIMS1, SNAP25, STX1B, STXBP1, SYT1
KEGG:04110 Cell cycle 8 6.451613 3.53E-03 ABL1, CDKN1A, MDM2, MYC, SMAD2, TP53, YWHAG, YWHAQ
KEGG:04912 GnRH signaling pathway 7 7.6086955 3.60E-03 CAMK2A, CAMK2B, EGFR, GRB2, JUN, MAP3K3, SRC
KEGG:05212 Pancreatic cancer 6 9.090909 4.12E-03 AKT1, EGFR, IKBKG, SMAD2, STAT1, TP53
KEGG:04713 Circadian entrainment 7 7.2916665 4.34E-03 CAMK2A, CAMK2B, FOS, GNAO1, GRIN1, GRIN2B, MTNR1A
KEGG:04380 Osteoclast differentiation 8 6.060606 5.02E-03 AKT1, FOS, FYN, GRB2, IKBKG, JUN, STAT1, TRAF6
KEGG:05160 Hepatitis C 8 6.0150375 5.14E-03 AKT1, CDKN1A, EGFR, GRB2, IKBKG, STAT1, TP53, TRAF6
KEGG:04068 FoxO signaling pathway 8 5.970149 5.25E-03 AGAP2, AKT1, CDKN1A, EGFR, GABARAPL2, GRB2, MDM2, SMAD2
KEGG:04917 Prolactin signaling pathway 6 8.333333 5.77E-03 AKT1, ESR2, FOS, GRB2, SRC, STAT1
KEGG:05142 Chagas disease (American trypanosomiasis) 7 6.730769 6.15E-03
AKT1, FOS, GNAO1, IKBKG, JUN, 
SMAD2, TRAF6
KEGG:04660 T cell receptor signaling pathway 7 6.6666665 6.31E-03 AKT1, FOS, FYN, GRB2, IKBKG, JUN, NCK1
KEGG:04725 Cholinergic synapse 7 6.3063064 8.59E-03 AKT1, BCL2, CAMK2A, CAMK2B, FOS, FYN, GNAO1
KEGG:05213 Endometrial cancer 5 9.615385 9.08E-03 AKT1, EGFR, GRB2, MYC, TP53
KEGG:04724 Glutamatergic synapse 7 6.140351 9.39E-03 DLG4, DLGAP1, GNAO1, GRIN1, GRIN2B, SHANK1, SLC1A3
Continued
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and in growth cones. For this reason, PSD-95, synaptophysin and GAP-43 were selected for additional biochem-
ical validation (i.e., immunoblotting). Briefly, co-IPs were carried out for BRI2, PSD-95, synaptophysin and 
GAP-43 from the cerebral cortex using a specific antibodies, and the respective mock negative controls. Analyses 
were carried out by SDS-PAGE and immunoblotting (Fig. 5). First, it was possible to confirm that the BRI2 
co-immunoprecipitation approach was effective, as when a BRI2 antibody was used in immunoblotting, a signal 
in the range of 37–40 kDa was detected, corresponding to the full-length BRI2 protein (Fig. 5A). Complexing 
with each of mentioned proteins was confirmed given that by using the PSD-95, synaptophysin and GAP-43 
specific antibodies, a positive signal for each of these interactors was obtained. In each case the BRI2 co-IP are 
consistent with the molecular weights; PSD-95 (95–100 KDa), synaptophysin (37 KDa) and GAP-43 (43 KDa) 
(Fig. 5A). The reverse co-immunoprecipitations were also effective, since specific PSD-95 (Fig. 5B), synapto-
physin (Fig. 5C) and GAP-43 (Fig. 5D) antibodies co-IPed full-length BRI2. Therefore, these results validate the 
mass spectrometry data, corroborating the formation of a three novel containing BRI2 complexes with PSD-95, 
synaptophysin and GAP-43 (Fig. 3 and Table 1).
Discussion
BRI2 is a relevant protein in the pathogenesis of the neurodegenerative diseases FBD and FDD, as well as in AD, 
given its association with APP and its effects on Abeta production, aggregation and degradation7,8,20,21. Several 
lines of evidence suggest a role for BRI2 at the nerve terminals4 and in neurite outgrowth3,5,6, however, its pre-
cise physiological function and associated signalling pathways remain elusive. The study of PPI networks is a 
valuable methodology to uncover the role of previously uncharacterized proteins in pathways or protein com-
plexes, both in healthy and diseased states. Therefore, the identification of the BRI2 interactome is crucial for 
understanding the biological functions of BRI2 in the CNS. This study focused on elucidating and characteriz-
ing the BRI2 brain interactome, which was isolated from rat cerebral cortex, hippocampus and cerebellum by 
co-immunoprecipitation assays, using a specific BRI2 antibody. This approach identified 511 protein candidates 
as potential BRI2 brain interactors, of which two were previously reported in public protein interaction databases: 
Ppp1ca and Cacna2d1. PP1 is a major serine/threonine phosphatase that was recently found to interact directly 
with BRI2. The BRI2:PP1 complex seems to be relevant in the nervous system since BRI2 dephosphorylation by 
PP1 appears to be responsible for both the regulation of BRI2 processing and its role in neurite outgrowth5,6. In 
total, only two of the previously reported BRI2 interactors (Supplementary Table S3) were identified in the work 
here presented. Of note, only a small number of these previously reported BRI2 interacting proteins have actually 
been validated. Moreover, the failure to identify other known BRI2 interactors might be due to several factors. For 
instance, limitations of this study include the possibility of poor recovery of the membrane and nuclear proteins, 
not detecting weak or transient interactions, and the cellular/tissue expression of the proteins previously detected. 
It is also crucial to take into account that the HPLC-MS/MS technique identifies co-complex interactions which 
include direct physical interactions but also indirect co-complex associations22. Remarkably, although the BRI2 
interactors here identified do not present a high overlap with the others previously reported in the literature, 
many were functionally similar or related. It is also important to note that a specific BRI2 antibody that recog-
nizes the N-terminal of the protein was used. Since BRI2 suffers proteolytic cleavages that originate different 
BRI2 N-terminal fragments, it is possible that the co-IP experiments result in both the full-length BRI2 and the 
different BRI2 N-terminal fragments.
In this study, the BRI2 brain interactome was identified, and thus a tissue-specific network-based approach 
was used. Of the 511 candidate BRI2 brain interactors identified in this study, 120 were highly specific or strongly 
expressed in the brain. Functional enrichment analysis for cellular component of the BRI2 ES interactome sug-
gests a subcellular localization for the BRI2 protein in neuron projections, synapses, both presynapse, and post-
synapse, and associated with synaptic vesicles (Fig. 2B). These results together with the fact that the majority of 
these BRI2 interactors are cytoskeletal proteins, transporters and membrane traffic proteins (Fig. 1) are consistent 
KEGG Term ID KEGG Term
Nr. 
Genes
% Associated 
Genes pValue Associated Genes Found
KEGG:04919 Thyroid hormone signaling pathway 7 5.9322033 1.11E-02 AKT1, MDM2, MYC, RXRB, SRC, STAT1, TP53
KEGG:05223 Non-small cell lung cancer 5 8.928572 1.14E-02 AKT1, EGFR, GRB2, RXRB, TP53
KEGG:04720 Long-term potentiation 5 7.4626865 2.51E-02 CAMK2A, CAMK2B, GRIN1, GRIN2B, PPP1CA
KEGG:04066 HIF-1 signaling pathway 6 5.8252425 2.68E-02 AKT1, BCL2, CAMK2A, CAMK2B, CDKN1A, EGFR
KEGG:04210 Apoptosis 7 5.0 2.71E-02 AKT1, BCL2, BID, FOS, IKBKG, JUN, TP53
KEGG:04620 Toll-like receptor signaling pathway 6 5.6603775 2.81E-02 AKT1, FOS, IKBKG, JUN, STAT1, TRAF6
KEGG:05218 Melanoma 5 7.0422535 2.83E-02 AKT1, CDKN1A, EGFR, MDM2, TP53
KEGG:04662 B cell receptor signaling pathway 5 6.849315 2.89E-02 AKT1, FOS, GRB2, IKBKG, JUN
KEGG:04520 Adherens junction 5 6.756757 2.90E-02 CSNK2B, EGFR, FYN, SMAD2, SRC
KEGG:05145 Toxoplasmosis 6 5.084746 3.83E-02 AKT1, BCL2, GNAO1, IKBKG, STAT1, TRAF6
KEGG:05030 Cocaine addiction 4 8.163265 4.04E-02 DLG4, GRIN1, GRIN2B, JUN
Table 2. KEGG category enrichment analysis of the neuronal differentiation annotated network obtained using 
ClueGo plugin of the Cytoscape software. Enriched categories identified are those with p-value < 0.05.
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with the concept that BRI2 in the CNS has a role in nerve terminals and neuronal differentiation3–6. Analysis of 
the BRI2 ES interactome resulted in the identification of proteins associated with several processes of the synaptic 
vesicle cycle, such as neurotransmitter uptake and vesicle docking, priming, fusion and exocytosis (Fig. 2A and 
Supplementary Table S5).
Moreover, several proteins in the BRI2 ES interactome associated with the microtubule transport machinery 
were found, in particular, β-tubulin isotype III (Tubb3b), β-tubulin isotype IIb (Tubb2b), kinesin heavy chain iso-
forms 5a and 5c (Kif5a and kif5c, respectively), and kinesin light chain isoform 1 (Klc1). Therefore, these results 
suggest that in neurons, BRI2 is transported within axons by anterograde axonal transport to the distal nerve 
terminals where the full-length protein or even its N-terminal fragments may interact with the neurotransmitter 
machinery release and contribute to synaptic signalling.
The present results regarding the BRI2 ES interactome also suggest an association for BRI2 with synaptic 
transmission, plasticity, and learning. Several BRI2 brain interactome members including disk large homolog 
4 (Dlg4/PSD-95), calcium/calmodulin-dependent protein kinase II alpha (Camk2a/CamkIIα), calcium/
calmodulin-dependent protein kinase II beta (Camk2b/CamkIIβ), protein phosphatase 1 (PP1/Ppp1ca), (glu-
tamate receptor ionotropic NMDA1 (Grin1/NR1/GluN1), glutamate receptor ionotropic NMDA2B (Grin2b/
GluN2B/NR2B), glutamate receptor ionotropic AMPA1 (Gria1/GluA1/GluR-1) and glutamate receptor iono-
tropic AMPA2 (Gria2/GluA2/GluR-2) participate in these processes. The PSD-95 protein was identified in our 
interactome firstly by MS analysis (Fig. 3) and further validated by immunoblotting analysis as novel BRI2 inter-
actor (Fig. 5), suggesting the presence of BRI2 in the postsynaptic compartments. One previous study by using 
gene-targeted affinity purification in mice (TAP-tagged PSD-95 knockin mice) followed by mass-spectrometry 
identification allowed the identification of several known and new putative PSD-95 interactors in mice brain 
extracts, and BRI2 was not identified23. However, we should mention that routinely affinity purification coupled 
to mass spectrometry protocols recovers only the most stable interactions, and the transient biological interac-
tions in nature that depends on the cellular environment can be missed.
PSD-95 is a major scaffold protein in the brain and concentrated in the postsynaptic density (PSD) of excit-
atory synapses, implicated in synapse maturation and in regulating synaptic strength and plasticity24–26. PSD-95 
interacts with both AMPA receptors (AMPARs) and NMDA-type glutamate receptors (NMDARs). Therefore, it 
is plausible to hypothesize that BRI2 may also be involved in synaptic transmission and plasticity by altering the 
AMPAR and NMDAR trafficking which affects excitatory synaptic transmission. Consistent with a role for BRI2 
in synaptic plasticity, learning and memory, Itm2b (+/−) mice exhibit synaptic and memory deficits. Knock-in 
mouse models of FDD and FBD, FDDKI and FBDKI respectively, exhibit similar deficits which are attributed to 
the loss of BRI2 function in those neurodegenerative diseases27,28. Moreover, in a synaptosomal proteome charac-
terization of the mouse model FDDKI, PSD-95 expression was found decreased and pointed as a potential player 
in the altered synaptic transmission and activity observed in this mice29. PSD-95 knockout mice display several 
phenotypic similarities, such as abnormal synaptic plasticity as well as abnormal memory and learning30.
An exciting feature of these BRI2 interactomes is the high number of cytoskeleton proteins which translated 
into an overrepresentation of functions like cytoskeleton organization and microtubule-based processes, evi-
dently important for neuronal differentiation (Fig. 2A). Rearrangements of actin and microtubules cytoskele-
tons are crucial to establish and maintain polarity in neurons, in neural migration and vesicle trafficking31,32. 
In fact, almost 50% (49 out of the 120) of the brain BRI2 ES interactome proteins are annotated with neuronal 
differentiation related biological processes (Supplementary Table S7), and the construction of a BRI2-neuronal 
differentiation-specific PPI subnetwork (Fig. 3) allowed us to explore the biological functionalities and the 
potential underlying molecular mechanisms of BRI2 in these processes. In line with this observation, functional 
enrichment pathway analysis of the expanded BRI2-neuronal differentiation-specific interactome associated 
BRI2 interactors to signalling pathways involved in several neuronal differentiation related events, namely adhe-
rens junction, axon guidance, ErbB signalling pathway33,34, FoxO signalling pathway35, neurotrophin signalling 
pathway36 and estrogen signalling pathway37 (Table 2). These results strengthen the proposed role for BRI2 in 
neuronal differentiation and neurite outgrowth and an association of BRI2 with these signalling pathways deserve 
further investigations.
The identification of adhesion proteins, such as neural cell adhesion molecule (Ncam1), a member of the Ig 
superfamily of cell-adhesion molecules38 in the study here presented leads us to propose that one of the mech-
anisms by which BRI2 promotes neurite outgrowth might be by regulating cell-cell adhesion. Ncam associates 
with numerous cytoskeletal components but also with some signalling pathways associated with a neurite out-
growth response39. For instance, Ncam interacts with spectrin, a protein involved in linking cellular membranes 
to the actin filament cytoskeletal system, which in turns interacts with the growth-associated protein 43 (GAP-
43), a protein that is highly expressed in growth cones and believed to be important for growth cone extension. 
Likewise, Ncam-mediated neurite outgrowth was inhibited in neurons from GAP-43 knockout mice, supporting 
a functional relationship between Ncam and GAP-4339. Remarkably, both spectrin (Sptbn2) and GAP-43 (Gap43) 
were identified in our BRI2 interactome and therefore these mechanisms deserve further investigation. Moreover, 
it has already been described that BRI2 is able to form homodimers linked by disulfide bonds that appear at the 
cell surface resembling the structure of a cell-surface receptor40. Although a receptor function for BRI2 has not 
been established it is possible to hypothesize that BRI2, triggered by ligand interaction, may act as a cell sur-
face receptor participating in the above-mentioned signalling pathways. It was recently demonstrated by our 
group that BRI2 phosphorylation modulates its proteolytic processing and neuritogenic role. Moreover, for BRI2 
mediated neurite outgrowth, it appears that phosphorylation of full-length protein promotes the emergence of 
neurites whereas the increased BRI2 NTFs play a relevant role in neurites’ elongation and stabilization6. Thus, it is 
also plausible to assume that mechanisms underlying BRI2 role in neurite outgrowth may also involve: (1) BRI2 
full-length phosphorylation induces conformational changes in the protein which affect protein-protein binding, 
and for instance could affect binding to neurotrophic effectors of the above signalling pathways; (2) increased 
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BRI2 proteolytic processing to its secreted fragment (containing the BRICHOS domain) which can activate the 
above signalling pathways via a growth factor receptor.
Finally, a comparative analysis approach of the BRI2 ES interactome in the three different brain regions was 
employed, resulting in the identification of 31 proteins specifically in the cerebral cortex, 14 in the hippocampus, 
and 8 in the cerebellum (Fig. 4C). The results evidenced that in the different brain regions BRI2 seems to be asso-
ciated with cellular processes also highlighted in the analysis of the total BRI2 ES interactome, namely neuron 
Figure 4. Brain region specific protein interactions in the BRI2 interactome. (A,B) Brain region specific 
protein interactions revealed in the identified BRI2 interactome. (A) Venn diagram comparison of the brain 
region (cerebral cortex, hippocampus, and cerebellum) specific BRI2 protein interactions identified in this 
study. (B) BRI2 interactome identified in this study. Node size according to the degree in the network. Edge 
color represents the source of interaction: blue edges correspond to the BRI2 interactions identified in the 
cerebral cortex, orange edges correspond to the BRI2 interactions identified in the hippocampus, and green 
edges correspond to the BRI2 interactions identified in the cerebellum. (C,D) Brain region specific protein 
interactions revealed in the identified BRI2 ES interactome. (C) Venn diagram comparison of the brain region 
(cerebral cortex, hippocampus, and cerebellum) specific BRI2 protein interactions identified in this study, 
highly enriched or specific for the brain. (D) BRI2 ES interactome identified in this study. Node size according 
to the degree in the network. Edge color represents the source of interaction: blue edges correspond to the BRI2 
interactions identified in the cerebral cortex, orange edges correspond to the BRI2 interactions identified in the 
hippocampus, and green edges correspond to the BRI2 interactions identified in the cerebellum.
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GO term
Nr. 
proteins
Fold enrichment 
(%) p-value Associated proteins
BRI2 ES cerebral cortex specific network analysis
synaptic vesicle fusion to presynaptic active 
zone membrane (GO:0031629) 9 55.78 1.28E-09
SNAP25, SNAP23, SNAP47, STX3, STX2, 
SNAP29, STX11, STX1A, STX4
vesicle fusion with Golgi apparatus 
(GO:0048280) 6 44.62 5.70E-05 VTI1B, SEC. 22B, BET1, GOSR2, STX5, SEC. 22 A
dendrite morphogenesis (GO:0048813) 9 13.66 2.62E-04 DLG4, ITGB1, FYN, DCX, ABI1, SHANK3, SHANK1, CAMK2A, MAP2
protein localization to membrane 
(GO:0072657) 22 4.07 3.48E-04
RTP2, TNF, VAMP4, VAMP3, VAMP2, DLG4, 
SNAP25, ITGB7, SNAP47, NUP54, DLG2, 
TMED2, STX3, SHANK3, DLG1, DLG3, STX1A, 
NSF, VAMP5, EGFR, RPS8, TNIK
learning (GO:0007612) 13 7.11 5.05E-04
DLG4, SNAP25, SLC8A2, ITGB1, SHANK2, FYN, 
HTT, SHANK3, ATP1A2, SHANK1, APP, PARK2, 
GRIN1
regulation of protein localization to plasma 
membrane (GO:1903076) 10 10.47 5.25E-04
VTI1B, ITGB1, PIK3R1, STX8, STX3, GOPC, 
DLG1, STX7, EGFR, STX4
ERBB2 signaling pathway (GO:0038128) 8 15.26 6.70E-04 GRB2, CDC37, PTPN12, SRC, PIK3R1, ERBB4, ERBB2, EGFR
long-term synaptic potentiation 
(GO:0060291) 8 14.87 8.11E-04
VAMP2, SNAP25, SLC8A2, SHANK2, SNAP47, 
STX3, SHANK3, STX4
retrograde vesicle-mediated transport, Golgi 
to ER (GO:0006890) 10 9.18 1.74E-03
TMED9, RINT1, SEC. 22B, KDELR1, TMED2, 
KIF18A, HTT, USE1, BNIP1, NSF
retrograde transport, endosome to Golgi 
(GO:0042147) 10 9.07 1.95E-03
TRIM27, VAMP3, TMED9, DCTN1, VTI1B, 
STX10, STX16, GOSR2, STX5, STX6
post-Golgi vesicle-mediated transport 
(GO:0006892) 10 8.55 3.32E-03
VAMP4, VAMP3, VAMP2, VTI1B, SNAP23, 
GOSR2, GOPC, NSF, VAMP5, STX4
receptor localization to synapse 
(GO:0097120) 5 33.80 4.14E-03 DLG4, DLG2, ANKS1B, DLG1, DLG3
regulation of ion transport (GO:0043269) 25 3.17 4.50E-03
TRIM27, CREB3, VAMP3, KCNA3, PRKACA, 
VAMP2, PLN, DLG4, GPM6B, YWHAE, KCNA1, 
PLCG1, HTT, SHANK3, ATP1A2, PRKCD, 
ATP2B2, ABL1, HOMER1, SHANK1, DLG1, 
CALCA, KCNA10, CAMK2A, PARK2
vesicle-mediated transport to the plasma 
membrane (GO:0098876) 9 9.70 4.52E-03
VAMP4, VAMP3, VAMP2, SNAP25, SNAP47, 
STX3, GOPC, NSF, VAMP5
positive regulation of excitatory 
postsynaptic potential (GO:2000463) 6 20.28 5.65E-03
RIMS1, DLG4, SHANK3, SHANK1, STX1A, 
GRIN1
GDP metabolic process (GO:0046710) 5 28.60 9.33E-03 MAGI3, DLG4, DLG2, DLG1, DLG3
neuromuscular process (GO:0050905) 10 7.36 1.25E-02 DLG4, KCNA1, PTPRQ, SHANK3, ATP2B2, ABL1, SHANK1, APP, PARK2, GRIN1
SNARE complex assembly (GO:0035493) 4 49.58 1.33E-02 VAMP4, VAMP3, VAMP1, STX4
protein localization to synapse 
(GO:0035418) 6 17.16 1.47E-02 DLG4, SNAP25, SNAP47, STX3, SHANK1, PCLO
regulation of intracellular transport 
(GO:0032386) 22 3.24 1.54E-02
CREB3, TNF, VAMP3, RIMS1, VAMP2, PLN, 
NAPB, SRC, EMD, YWHAE, RINT1, NUP54, 
PIK3R1, RNASE2, ERBB4, ERBB2, PRKCD, 
HMOX1, MDM2, STX1A, PARK2, EGFR
peptidyl-tyrosine phosphorylation 
(GO:0018108) 13 5.14 1.83E-02
TRIM27, INSR, CDC37, SRC, ABI3, FYN, PIBF1, 
ERBB4, ERBB2, ABI1, PRKCD, ABL1, EGFR
COPII vesicle coating (GO:0048208) 8 9.75 1.86E-02 GOLGA2, GRIA1, SEC. 22B, BET1, TMED2, GOSR2, STX5, NSF
activation of protein kinase activity 
(GO:0032147) 16 4.09 2.38E-02
TNF, AGAP2, INSR, ITGB3, PRKACA, SRC, 
PIBF1, CRK, PLCG1, PRKCD, ABL1, CD81, 
DLG1, CALCA, EGFR, TNIK
synaptic vesicle docking (GO:0016081) 4 37.18 4.12E-02 SNAP25, STX3, BLOC1S6, STX1A
BRI2 ES hippocampus specific network analysis
synaptic vesicle fusion to presynaptic active 
zone membrane (GO:0031629) 7 77.92 6.23E-08
STX19, STX1B, STX3, STX2, SNAP29, STX1A, 
STX4
cytoskeleton organization (GO:0007010) 28 3.97 3.85E-06
CRMP1, PFN1, DPYSL3, UBE2B, MYO18A, 
KLHL20, DPYSL2, ACTR2, SRC, FLNA, ADD2, 
DBN1, SDCBP, LIMA1, ZAK, ANK2, KIF18A, 
HTT, PIP5K1A, ANLN, SPRY2, SEPT1, SYNE4, 
CCDC155, AXIN1, MYH9, VIM, CDK5RAP2
vesicle docking (GO:0048278) 9 20.73 6.79E-06 STX19, STX1B, STX3, STX2, STX16, STX5, STX1A, STX4, STX6
intracellular protein transport 
(GO:0006886) 23 4.15 7.66E-05
AP3M1, CDC37, NAPB, STX19, EHD3, YWHAE, 
SDCBP, STX1B, VCP, STX3, MICALL1, ANK2, 
STX2, PIP5K1A, MYO1C, MCM3AP, STX16, BID, 
STX5, ARL6IP1, STX1A, STX4, STX6
Continued
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development and synaptic vesicle cycle (Table 3), supporting that the majority of the biological functions of BRI2 
in the CNS are in fact relatively stable across the three brain regions.
In summary, these results provide important insights on BRI2 brain interactome, comprising several new 
putative interacting partners. We observed a complex interaction of BRI2 with proteins related to neuronal dif-
ferentiation, neurite outgrowth, synaptic signalling and plasticity. Further, we validated PSD-95, synaptophysin 
and GAP-43 as novel BRI2 interactors in the brain using co-IP and immunoblotting analysis. Therefore, the work 
here presented provides a valuable list of BRI2 interacting proteins for further studies to investigate their poten-
tial roles in BRI2 biology and the underlying molecular mechanisms, as well as novel insights in its associated 
pathologies (FBD, FDD, and AD).
Methods
Preparation of rat brain lysates. Wistar Hannover rats (9–12 weeks) were obtained from Harlan 
Interfaune Ibérica, SL, and all experimental procedures were conducted in accordance with the European legis-
lation for animal experimentation (2010/63/EU). No specific ethics approval under EU guidelines was required 
for this project, since the rats were euthanized, by cervical stretching followed by decapitation, for brain removal. 
This is within the European law (Council Directive 86/609/EEC) and the number and suffering of the ani-
mals were minimized as much as possible. The procedures were approved and supervised by our Institutional 
GO term
Nr. 
proteins
Fold enrichment 
(%) p-value Associated proteins
cell projection organization (GO:0030030) 25 3.23 1.95E-03
CRMP1, MAPK8IP2, UBE2B, IQCB1, RTN4, 
DPYSL2, HMGB1, ACTR2, SRC, FLNA, EHD3, 
TMEM17, YWHAE, SDCBP, RPS6KA5, LIMA1, 
INTU, STX3, MICALL1, IQGAP1, PIP5K1A, 
SNAP29, SLC12A5, MYH9, CDK5RAP2
Golgi vesicle transport (GO:0048193) 14 5.62 2.22E-03
MYO18A, KLHL20, EHD3, RBSN, BET1, 
TFG, VCP, ANK2, KIF18A, HTT, STX5, STX4, 
ANKFY1, STX6
spindle localization (GO:0051653) 6 20.04 5.83E-03 ACTR2, HTT, SPRYZ, CCDC155, MYH9, CDK5RAP2
cell differentiation (GO:0030154) 50 1.95 1.00E-02
CRMP1, DPYSL3, MAPK8IP2, UBE2B, MAPK6, 
RTN4, ATF2, DPYSL2, HMGB1, ACTR2, SRC, 
FLNA, AGR2, DBN1, IL33, YWHAE, PSMD11, 
RPS6KA5, BASP1, STX1B, INTU, STX3, 
CDK5RAP3, ZAK, MICALL1, ANK2, IQGAP1, 
STX2, RNF8, FXR1, PIP5K1A, ANLN, SMPD3, 
SPRY2, HNRNPH3, RIPK3, SYNE4, SLC12A5, 
HSPE1, CCDC155, AXIN1, GNB2L1, MYH9, 
ANXA7, VIM, TRIP13, CDK5RAP2, CPNE9, 
FAS, RGS2
protein complex assembly (GO:0006461) 23 3.04 1.75E-02
DPYSL3, MAPK8IP2, TK1, RTN4, SRC, ADD2, 
EHD3, PSMD11, BET1, TFG, VCP, CADPS, 
NDUFV2, STX2, AMFR, ANLN, SNAP29, RIPK3, 
BID, STX5, AXIN1, STX4, FAZ
regulation of cysteine-type endopeptidase 
activity involved in apoptotic process 
(GO:0043281)
10 6.61 2.92E-02 HMGB1, SRC, YWHAE, VCP, SERPINB9, BID, ARL6IP1, HSPE1, GNB2L1, FAZ
actin filament-based process (GO:0030029) 15 4.14 3.50E-02
PFN1, DPYSL3, MYO18A, ACTR2, SRC, FLNA, 
ADD2, DBN1, SDCBP, LIMA1, ANK2, PIP5K1A, 
CCDC155, MYH9, VIM
supramolecular fiber organization 
(GO:0097435) 13 4.72 3.97E-02
DPYSL3, ACTR2, SRC, FLNA, ADD2, DBN1, 
LIMA1, KIF18A, RIPK3, CCDC155, AXIN1, VIM, 
HSP90AB1
positive regulation of intracellular signal 
transduction (GO:1902533) 21 3.08 4.21E-02
MAPK8IP2, RGL2, PELI2, HMGB1, SRC, FLNA, 
SDCBP, TFG, CDK5RAP3, ZAK, IQGAP1, HTT, 
PLA2G2A, SPRY2, RIPK3, BID, CCL18, AXIN1, 
GNB2L1, EEF1D, FAS
cytosolic transport (GO:0016482) 8 8.62 4.29E-02 KLHL20, ACTR2, EHD3, RBSN, STX16, STX5, ANKFY1, STX6
BRI2 ES cerebellum-specific network analysis
synaptic vesicle recycling (GO:0036465) 4 60.13 5.56E-03 SH3GL2, SYT2, SYT7, SH3GL1
endocytosis (GO:0006897) 9 7.44 2.22E-02 SH3GL3, SH3GL2, WIPF1, DPYSL2, SYT2, SYT7, CSNK1E, SH3GL1, CACNG2
developmental process (GO:0032502) 28 2.42 2.29E-03
SH3GL3, COL10A1, SH3GL2, GFI1B, DPYSL4, 
DPYSL2, PRKD2, RHEB, SYT2, SIAH1, ITM2B, 
KIF18A, PTPRO, HTT, SRPK2, CSNK1E, 
SH3GL1, SPRED1, TFF1, LITAF, SYNE4, UCHL1, 
CCDC155, TRIP13, ARIH2, SPRY3, SPRED2, 
NCAM1
Table 3. Biological process enrichment analysis of the BRI2 ES regional specific networks (cerebral cortex, 
hippocampus, and cerebellum) using Panther online resource. Enriched categories are identified as those with 
p-value < 0.05, and GO terms presented correspond to the two most specific for each category retrieved in the 
analysis. Nr. Number.
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Animal Care and Use Committee (IACUC): Comissão Responsável pela Experimentação e Bem-Estar Animal 
(CREBEA). Briefly, animals were sacrificed by cervical stretching followed by decapitation and the cerebral cor-
tex, hippocampus and cerebellum were dissected on ice. Tissues were further weighed and homogenized on ice 
with a Potter-Elvehjem tissue homogenizer with 10–15 pulses at 650–750 rpm, in non-denaturating lysis buffer 
(50 mM Tris-HCl pH 8.0, 120 mM NaCl and 4% CHAPS) containing protease inhibitors (1 mM PMSF, 10 mM 
Benzamidine, 2 µM Leupeptin, 1.5 µM Aprotinin and 5 µM Pepstatin A)41. The tissue extracts were used for 
immunoprecipitation analysis as described below.
Co-immunoprecipitation. The lysates from rat cerebral cortex, hippocampus and cerebellum extracts 
were divided into three equal parts (2 controls and 1 BRI2 co-immunoprecipitation) and pre-cleared separately 
using Dynabeads Protein G (Life Technologies). A direct immunoprecipitation approach was performed using 
mouse anti-BRI2 antibody (1 µg/500 µg protein; Cat. No. sc-374362, Santa Cruz Biotechnology), pre-incubated 
with Dynabeads Protein G for 1 hour at 4 °C with rotation. After, the pre-cleared extracts were applied to 
antibody-Dynabeads and incubated overnight at 4 °C with rotation. The immunoprecipitates were washed three 
times with PBS in 3% BSA for 10 min at 4 °C with rotation and beads were re-suspended in 1% SDS42. As a control 
extracts only incubated with dynabeads protein G or with dynabeads protein G coupled with mouse IgGs were 
used. Each brain region received the whole procedure three independent times.
In-gel protein digestion, nano-HPLC and mass spectrometry. The eluted fractions from the 
brain BRI2 co-IP assays were separated by SDS-PAGE on a 12% Bis-Tris gel and gels bands excised, cut into 
small pieces, and alternately washed with buffer A (50 mM ammonium hydrogen carbonate (NH4HCO3)) 
and B (50 mM NH4HCO3/50% ACN (acetonitrile)). Following dehydration of gel pieces in vacuo, trypsin 
(Serva, Germany) was solved in 10 mM HCl and 50 mM NH4HCO3 and used for overnight in gel digestion 
at 37 °C (trypsin:protein ratio 1:20). Peptides were then extracted once with 200 μl of 50% ACN/0.05% TFA 
(trifluoroacetic acid) and once with 100 μl of 50% ACN/0.05% TFA. Extracts were combined and centrifuged 
for 5 min at 16,000 × g. The supernatant was transferred to a new vial in order to get rid of potential gel resid-
uals. Then, ACN was removed in vacuo. For LC–MS analysis, a final volume of 16 μl was prepared by addition 
of 0.1% TFA.
Peptide extracts were used for mass spectrometry analysis. Therefore, samples were injected via the autosam-
pler of an RSLC nano system (Thermo Scientific), concentrated on a C18 trapping column (2 cm length, 100 μm 
i.d., 5 μm particle size, Thermo Scientific), and separated on a C18 analytical column (50 cm length, 75 μm i.d., 
2 μm particle size, Thermo Scientific) heated at 60 °C before being emitted via a coated silica tip (FS360-20-
10-D-20, New Objective, USA) of the nanospray-electrospray source of an Q Exactive (Thermo Scientific). The 
HPLC separation was performed with a gradient method of in total 120 min consisting of: 7 min of loading the 
sample and washing the column with 0.1% TFA at a flow rate of 30 μl min−1 on the trapping column, followed 
by separation applying a linear gradient at a flow rate of 400 nl min−1 with the solvents A (0.1% FA (formic acid) 
in HPLC grade water) and B (84% ACN/0.1% FA in HPLC grade water) starting from 5% B to 40% B in 98 min 
on the heated analytical column, a linear gradient of 40% B to 95% B in 2 min, and washing for 7 min with 95% 
B. Finally, a gradient was applied from 95% B to 5% B in 1 min followed by equilibration for 5 min with 5% B. 
Figure 5. Co-immunoprecipitation of BRI2, PSD-95, synaptophysin and GAP-43 in rat cerebral cortex lysate. 
Rat cerebral cortex lysate was immunoprecipitated with a mouse monoclonal BRI2 antibody (A), a mouse 
monoclonal PSD-95 antibody (B), a mouse monoclonal synaptophysin antibody (C) and a rabbit polyclonal 
GAP-43 antibody (D) bound to protein G dynabeads. The mock IP negative controls were performed by 
incubating cell extracts with G Dynabeads coupled with mouse IgG or rabbit IgG. NC, mock IP negative 
controls. Arrows indicate BRI2 N-terminal fragments detected in brain lysates.
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For ionization a spray voltage of 1.6 kV and capillary temperature of 250 °C was used. The acquisition method 
consisted of two scan events, Full MS and MS/MS. The Full MS was monitored from m/z 350 to 1400, with an 
Orbitrap resolution of 70,000, a maximum injection time of 80 ms and an automatic gain control (AGC) value 
of 3e6. The m/z values initiating MS/MS were set on a dynamic exclusion list for 35 s. Lock mass polydimethyl-
cyclosiloxane (m/z 445.120) was used for internal recalibration. The 10 most intensive ions (charge N1) were 
selected for MS/MS-fragmentation and fragments were scanned at a resolution of 35,000, with a maximum injec-
tion time of 120 ms and an AGC value of 2e5. Fragments were generated by higher-energy collisional-induced 
dissociation (HCD) on isolated ions.
For peptide identification.raw files were processed in Proteome Discoverer 1.4 and analyzed using the Mascot 
search algorithm with a mass tolerance of 10 ppm and a fragment mass tolerance of 0.02 Da. Searches were per-
formed allowing one missed cleavage site after tryptic digestion. Oxidation (M) and phosphorylation (STY) were 
considered as variable modifications. Targeted Decoy PSM Validator was implemented with an FDR of 1%. All 
data were searched against a database containing the whole Uniprot/Swissprot entries of the taxonomy Rattus 
norvegicus.
For each sample condition (i.e. for each specific brain region), two mock IPs were used as negative controls. 
Therefore, the proteins identified in the mock IPs were excluded from the list of the proteins identified in the 
BRI2 co-IPs, with one exception: the ratio between the number of peptide spectrum matches (PSM) for a given 
protein in a BRI2 co-IP sample and the PSM in the mock IPs, of the same brain region, were equal or higher than 
2.0. In addition, well-described common contaminants as presented in43 and proteins characteristic of hair, skin/
epidermis, tongue and gums (KRT33A, KRT78, KRT85, KRT14, KRT5, KRT3, KRT31, KRT32, KRT33B, KRT35, 
KRT36, KRT4, KRT77, KRT8, KRT17) which are also highly probable contaminants, were excluded.
Bioinformatic data analysis. Experimentally detected BRI2 protein-protein interactions already described 
in the literature were retrieved using PSIQUIC View web service44 (version 1.4.5, downloaded October 2016), 
which enabled access to multiple PSI-MI compliant resources. In addition, two BRI2 interacting proteins iden-
tified and validated recently in our laboratory, protein phosphatase 1 alpha (PPP1CA) and protein phosphatase 
1 gamma (PPP1CC), were added manually.
Tissue expression analysis was performed using the following databases: The Human Protein Atlas (HPA; 
available from www.proteinatlas.org)45; TiGER (available from http://bioinfo.wilmer.jhu.edu/tiger)46; and 
UniGene47. The HPA was searched for proteins strongly expressed in the brain and a list of proteins within the 
brain ‘Tissue enriched’, ‘Tissue enhanced’ and ‘Group enriched’ categories was obtained. Annotated protein 
expression is a manually curated score based on IHC staining patterns in normal tissues from two or more paired 
antibodies binding to different epitopes of the same protein, which describes the distribution and strength of 
expression of each protein in cells. The TiGER database was searched for proteins, preferentially expressed in the 
brain, based on ESTs by searching ‘Brain’ in ‘Tissue View’. The UniGene database was searched for brain-restricted 
genes by using the following search criteria: [brain][restricted].
Functional enrichment analysis of Gene Ontology (GO) categories (biological process and cellular compo-
nent) was performed using PANTHER (Protein Annotation Through Evolutionary Relationship; version 11.1, 
accessed January 2016), online resource48. For the PANTHER enrichment analysis, the overall set of rat/human 
protein-coding genes were used as a reference set, and only enriched annotation with a p-value < 0.05 were 
considered. In addition, functional enrichment analysis of KEGG pathways was performed using the ClueGo 
plugin version 2.3.219, (accessed January 2016) of the Cytoscape software version 3.4.0, freely available online15. 
Construction of protein-protein interaction (PPI) networks was achieved also using the Cytoscape software 
and further analyzed using the NetworkAnalyzer plugin version 3.3.1 (accessed January 2016). In order to 
perform network augmentation, protein-protein data was retrieved from the International Molecular Exchange 
(IMEx) consortium partners. Given the lack of information for Rattus norvegicus in these databases, the lists 
of proteins were extrapolated by homology to Homo sapiens. Rat UniProt accession numbers were converted 
to human using the Uniprot tool available online - Uniprot Retrieve/ID mapping (http://www.uniprot.org/
uploadlists/)49–66.
Interaction validation by immunoblotting. In order to validate BRI2 interactions, immunobloting 
assays were carried out. Brain lysates and eluted proteins from the co-immunoprecipitation assays performed in 
rat cortex tissue were resolved on 5–20% gradient SDS-PAGE and electrophoretically transferred onto nitrocel-
lulose membranes. Moreover, additional co-immunoprecipitations were performed as described above, using a 
mouse anti-PSD-95 antibody (1 µg/100 µg protein; Cat. No. MAB1598; Millipore), a mouse anti-synaptophysin 
(5 µg/IP; Cat. No. 101011; Synaptic Systems) and a rabbit anti-GAP-43 antibody (1 µg/100 µg protein; Cat. No. 
442695; Calbiochem).
Nonspecific protein-binding sites were blocked using 5% nonfat dry milk in TBST. Afterward, the mem-
branes were incubated with the following primary antibodies: anti-BRI2 antibody (catalog no.: sc-374362, Santa 
Cruz Biotechnology) and anti-PSD95 (catalog no.: ab9708, Merck Millipore) overnight at 4 °C with shaking. The 
membranes were then washed three times for 10 minutes with TBST and incubated for 2 h at room temperature 
with horseradish peroxidase (HRP)-linked secondary antibodies (GE Healthcare). Finally, the membranes were 
washed three times for 10 minutes with TBST and enhanced chemiluminescence-based system were used for 
protein detection.
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